Aelis Farma Announces Positive Results of Non-clinical Studies Required by Regulatory Agencies to Enter Its First CB1-SSi, AEF0117, in Phase 3 Clinical Trial for the Treatment of Cannabis Use Disorder
Positive results of in vivo toxicology studies in which AEF0117 shows a favorable therapeutic index >13,000 time the active dose: Chronic oral toxicity studies (6 months in rats and 9…
Details